Stock A1LN34 ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Alnylam Pharmaceuticals, Inc. Sao Paulo

Equities

A1LN34

BRA1LNBDR003

Delayed Sao Paulo
Other stock markets
 17:21:50 28/06/2024 BST 		5-day change 1st Jan Change
67.55 BRL -.--% Intraday chart for Alnylam Pharmaceuticals, Inc. +52.86% +51.29%
06-28 UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
06-27 Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
AQ
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024
AQ
Alnylam Pharmaceuticals : HELIOS-B Topline Results Transcript
PU
Alnylam Pharmaceuticals : HELIOS-B Topline Results
PU
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
BU
Alnylam Issues 2023 Corporate Responsibility Report
BU
Alnylam Pharmaceuticals : 2023 REPORT
PU
Alnylam Pharmaceuticals : Q1 2024 GAAP/Non-GAAP Reconciliation ›
PU
Alnylam: Q1 Earnings Snapshot
AQ
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
BU
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
PR
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
BU
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
AQ
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
BU
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
BU
Alnylam Launches Hereditary ATTR Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
AQ
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
BU
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
PR
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure
AQ
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. A1LN34 Stock
  5. News Alnylam Pharmaceuticals, Inc.
  6. Press Releases